The Latest Cardiac and Vascular News
MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2021 revenue results, and provided a 2022 business outlook. Fourth Quarter […]
The Board of Acarix AB (publ) has today appointed Helen Ljungdahl Round as new Chief Executive Officer, with immediate effect. Helen is currently President of Acarix USA Inc. and will continue to be based in the US in her capacity as new group CEO of Acarix. Ms. Helen Ljungdahl Round […]
Series E Financing led by EW Healthcare Partners with Robert S. White to Join Board SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the completion of a $39 million round of financing, funded by EW Healthcare Partners in addition to other new […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2021 and provided 2022 financial guidance. Preliminary, unaudited revenue for fourth quarter 2021 […]
Acquisition to expand company’s cardiac ablation portfolio, including first-time entry into mapping and navigation, within one of the fastest growing medtech markets DUBLIN, Jan. 10, 2022 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has entered into a definitive agreement to acquire Affera, Inc., […]
SINGAPORE, Jan. 7, 2022 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) has appointed Dr. Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis’ technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include developing and implementing the Group’s global Vascular Interventions R&D strategy, driving the enhancement of […]
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif. and NEW YORK, Jan. […]
Fiscal 2022 Second Quarter Highlights Net sales of $78.3 million increased 7.6% compared to the prior-year quarter Med Tech growth of 36.4% and Med Device growth of 0.8% year over year Gross margin of 51.8% declined 340 basis points year over year GAAP loss per share of $0.21, and adjusted […]
SAN FRANCISCO and BETHPAGE, N.Y., Jan. 5, 2022 /PRNewswire/ — Housatonic Partners, a growth-oriented private equity firm focused on investing in market-leading services companies, announced a strategic growth investment in Mobile Vascular Physicians (“MVP”), a New York-based concierge medical practice that utilizes a specialized, mobile approach to provide vascular and interventional radiology services to residents […]
CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ — Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of David McIntyre as Chief Financial Officer. Mr. McIntyre will assume responsibility for the company’s finance and investor relation functions, and joins Anthos as its lead product candidate, abelacimab, expects […]
